According to the 2016 ACC/AHA guidelines on dual antiplatelet therapy (DAPT), when is treatment continued for more than a year, and when is treatment stopped after 6 months in NSTE-ACS or STEMI?

Updated: May 07, 2019
  • Author: A Maziar Zafari, MD, PhD, FACC, FAHA; Chief Editor: Eric H Yang, MD  more...
  • Print

Class IIb

In patients treated with coronary stent implantation or fibrinolytic therapy who have tolerated DAPT without a bleeding complication and who are not at high bleeding risk, continuation of DAPT (clopidogrel, prasugrel, or ticagrelor) for longer than 1 year may be reasonable. (Level of evidence: A)

After DES implantation, patients who develop a high risk of bleeding or are at high risk of severe bleeding complication, or who develop significant overt bleeding, discontinuation of P2Y12 inhibitor therapy after 6 months may be reasonable. (Level of evidence: C-LD)

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!